Immuno-Oncology Deal Trends, 2011–15

Immuno-Oncology Deal Trends, 2011–15

  • March 2016 •
  • 58 pages •
  • Report ID: 3993497 •
  • Format: PDF
Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups’ deal volume in immuno-oncology has grown over sevenfold from 2011 to 2015.

More than 50% of the immuno-oncology deals between 2011 and 2015 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies.

This report addresses the following questions:
- What is the growth of immuno-oncology deal-making over the last five years in volume and dollar value, and how does that compare with overall oncology deal-making?
- Who are the top players in immuno-oncology deal-making, and what were the structures of their key deals?
- Which solid and hematological tumor indications and anticancer immunotherapy targets are most involved immuno-oncology deals?
- What strategies are being implemented by some of the most influential companies in immuno-oncology?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.